Skip to main content
placeholder image

Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)

Journal Article


Download full-text (Open Access)

Abstract

  • In 2009 the International Stem Cell Banking

    Initiative (ISCBI) contributors and the Ethics

    Working Party of the International Stem Cell

    Forum published a consensus on principles of

    best practice for the procurement, cell banking,

    testing and distribution of human embryonic

    stem cell (hESC) lines for research purposes [1],

    which was broadly also applicable to human

    induced pluripotent stem cell (hiPSC) lines.

    Here, we revisit this guidance to consider what

    the requirements would be for delivery of the

    early seed stocks of stem cell lines intended for

    clinical applications.

Authors

  •   Andrews, Peter W. (external author)
  •   Baker, Duncan (external author)
  •   Benvinisty, N (external author)
  •   Miranda, B (external author)
  •   Bruce, K (external author)
  •   Brustle, O (external author)
  •   Choi, M (external author)
  •   Choi, Young Min (external author)
  •   Crook, Jeremy M.
  •   de Sousa, Paul A. (external author)

Publication Date

  • 2015

Citation

  • Andrews, P. W., Baker, D., Benvinisty, N., Miranda, B., Bruce, K., Brustle, O., Choi, M., Choi, Y. -M., Crook, J. M., de Sousa, P. A. et al (2015). Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regenerative Medicine, 10 (2s), 1-44.

Scopus Eid

  • 2-s2.0-84923189564

Ro Full-text Url

  • http://ro.uow.edu.au/cgi/viewcontent.cgi?article=4209&context=smhpapers

Ro Metadata Url

  • http://ro.uow.edu.au/smhpapers/3186

Has Global Citation Frequency

Number Of Pages

  • 43

Start Page

  • 1

End Page

  • 44

Volume

  • 10

Issue

  • 2s

Place Of Publication

  • United Kingdom

Abstract

  • In 2009 the International Stem Cell Banking

    Initiative (ISCBI) contributors and the Ethics

    Working Party of the International Stem Cell

    Forum published a consensus on principles of

    best practice for the procurement, cell banking,

    testing and distribution of human embryonic

    stem cell (hESC) lines for research purposes [1],

    which was broadly also applicable to human

    induced pluripotent stem cell (hiPSC) lines.

    Here, we revisit this guidance to consider what

    the requirements would be for delivery of the

    early seed stocks of stem cell lines intended for

    clinical applications.

Authors

  •   Andrews, Peter W. (external author)
  •   Baker, Duncan (external author)
  •   Benvinisty, N (external author)
  •   Miranda, B (external author)
  •   Bruce, K (external author)
  •   Brustle, O (external author)
  •   Choi, M (external author)
  •   Choi, Young Min (external author)
  •   Crook, Jeremy M.
  •   de Sousa, Paul A. (external author)

Publication Date

  • 2015

Citation

  • Andrews, P. W., Baker, D., Benvinisty, N., Miranda, B., Bruce, K., Brustle, O., Choi, M., Choi, Y. -M., Crook, J. M., de Sousa, P. A. et al (2015). Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regenerative Medicine, 10 (2s), 1-44.

Scopus Eid

  • 2-s2.0-84923189564

Ro Full-text Url

  • http://ro.uow.edu.au/cgi/viewcontent.cgi?article=4209&context=smhpapers

Ro Metadata Url

  • http://ro.uow.edu.au/smhpapers/3186

Has Global Citation Frequency

Number Of Pages

  • 43

Start Page

  • 1

End Page

  • 44

Volume

  • 10

Issue

  • 2s

Place Of Publication

  • United Kingdom